StockData
Exagen Inc. logo

Exagen Inc. (XGN) stock

XGNNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$3.90+0.14 (+3.72%)

Close on Nov 18, 2026Market cap $94.48MP/E –Yield –

Exagen net income

Net income is the profit left for shareholders after every expense, interest and tax.

Exagen's net income for the twelve months ending Jun 30, 2026 was -$18.92M. For fiscal 2025 it was -$19.95M. The highest annual figure on record is -$8.01M in fiscal 2018.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$19.95M–
FY2024Dec 31, 2024-$15.12M–
FY2023Dec 31, 2023-$23.69M–
FY2022Dec 31, 2022-$47.39M–
FY2021Dec 31, 2021-$26.85M–
FY2020Dec 31, 2020-$16.69M–
FY2019Dec 31, 2019-$12.04M–
FY2018Dec 31, 2018-$8.01M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.20M–
Q1 FY2026Mar 31, 2026-$3.97M–
Q4 FY2025Dec 31, 2025-$4.67M–
Q3 FY2025Sep 30, 2025-$7.09M–
Q2 FY2025Jun 30, 2025-$4.44M–
Q1 FY2025Mar 31, 2025-$3.75M–
Q4 FY2024Dec 31, 2024-$3.76M–
Q3 FY2024Sep 30, 2024-$5.03M–
Q2 FY2024Jun 30, 2024-$2.97M–
Q1 FY2024Mar 31, 2024-$3.36M–
Q4 FY2023Dec 31, 2023-$5.57M–
Q3 FY2023Sep 30, 2023-$5.42M–
Q2 FY2023Jun 30, 2023-$5.01M–
Q1 FY2023Mar 31, 2023-$7.69M–
Q4 FY2022Dec 31, 2022-$14.35M–
Q3 FY2022Sep 30, 2022-$8.10M–
Q2 FY2022Jun 30, 2022-$14.67M–
Q1 FY2022Mar 31, 2022-$10.27M–
Q4 FY2021Dec 31, 2021-$7.05M–
Q3 FY2021Sep 30, 2021-$7.18M–
Q2 FY2021Jun 30, 2021-$6.41M–
Q1 FY2021Mar 31, 2021-$6.21M–
Q4 FY2020Dec 31, 2020-$3.45M–
Q3 FY2020Sep 30, 2020-$4.31M–
Q2 FY2020Jun 30, 2020-$3.36M–
Q1 FY2020Mar 31, 2020-$5.56M–
Q4 FY2019Dec 31, 2019-$3.41M–
Q3 FY2019Sep 30, 2019-$3.14M–
Q2 FY2019Jun 30, 2019-$2.79M–
Q1 FY2019Mar 31, 2019-$2.70M–
Q4 FY2018Dec 31, 2018-$1.32M–
Q3 FY2018Sep 30, 2018-$1.76M–
Q2 FY2018Jun 30, 2018-$2.15M–
Q1 FY2018Mar 31, 2018-$2.79M–

More Exagen figures

See a number that looks wrong?